Opportunity:
Paterna Bioscience is a biotech company focused on the rapidly growing $20B+ infertility market. Paterna's lead product is focused on male infertility, a market currently estimated to be $4B and poised to expand dramatically as new male fertility solutions such Paterna's enter the market.
Services and products in the infertility market have historically focused on female infertility factors. There is a growing recognition of the significance of male infertility and the need for more investment in research and treatment options for men.
Paterna is addressing the 1.5 million failed IVF cycles annually by serving men with fertility challenges. Male infertility factors substantially contribute to about 50% of all infertility cases and we see this as this market ripe for disruption. Paterna addresses a significant gap in the market as there is currently no effective, FDA-approved therapeutic for male infertility.
Paterna's proprietary approaches to treating male infertility address critical biological issues overlooked by many competitors. The growing focus on male reproductive health presents an opportunity for Paterna to enhance market visibility and growth.
